Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3813 - Prevelance of cyp1b1 mutations among lung cancer patients


09 Oct 2016


Poster display


Piotr Sawrycki


Annals of Oncology (2016) 27 (6): 462-468. 10.1093/annonc/mdw385


P. Sawrycki1, M. Gąsior2, K. Domagalski3, J. Jarkiewicz-Tretyn2, M. Jackowski4

Author affiliations

  • 1 Oddzial Chemioterapii Nowotworow, Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, 87-100 - Torun/PL
  • 2 Pracownia Genetyki Nowotworów, NZOZ Poradnia Genetyki Nowotworów, Torun/PL
  • 3 Centre For Modern Interdisciplinary Technologies, Nicolaus Copernicus Univerity, Torun/PL
  • 4 Katedra I Klinika Chirurgii OgÓlnej, Gastroentorologicznej I Onkologicznej, Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Torun/PL


Abstract 3813


Lung cancer is the leading cause of cancer death in the world. The most important risk factor is smoking. Only about 10% of patients never smoked, on the other hand, only about 15% of smokers get lung cancer. One of the possibile reason can be individual, genetic factors. This is supported by the evidence of more frequent occurrence of this disease in first-degree relatives of patients with lung cancer. In addition, there are many reports about lung cancer relationships with certain genetic disorders.


Correlation of CYP1B1 gene polymorphisms (variants C142G, G355T and C4326G) with the risk of lung cancer was analyzed. The selection of these genes is associated with their impact on the transformation of carcinogens contained for instance in tobacco smoke (CYP1B1). The frequency of CYP1B1 polymorphisms between 112 patients with lung cancer and the control group, consisting of 100 neonatal umbilical cord blood, is compared. Patients were also evaluated in terms of gender, type of cancer, the amount of pack-years and age of onset. Association of genetic variations with lung cancer were analyzed in terms of single nucleotide polymorphisms, haplotypes and combination of genotypes.


Statistically significant higher incidence of G allele variants of C142G polymorphism and allele C of C4326G polymorphism in patients with lung cancer was found. G355T polymorphism showed no statistically significant differences in terms of allele frequencies between the compared groups. Haplotype GTC and haplotypes GT (C142G-G355T), GC (C142G-C4326G) and TC (G355T-C4326G) occur significantly more frequently in the lung cancer group. Genotype combinations containing allele G of polymorphic variants C142G occur significantly more often in patients with lung cancer.


The results demonstrate a significant relationship of some polymorphisms with the risk of developing lung cancer. Inclusion of genetic data into screening could contribute to more accurately determine the population at risk of lung cancer and improve the results of lung cancer screening.

Clinical trial identification

Legal entity responsible for the study

1. Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu 2. NZOZ Pracownia Genetyki Nowotworów w Toruniu


1. Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu 2. NZOZ Pracownia Genetyki Nowotworów w Toruniu


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings